Aktana Announces First-To-Market GenAI Agents That Survive CRM Transitions
5.12.2024 16:00:00 CET | Business Wire | Press release
Aktana’s New Products Fortify Technology Stacks for the Future
Aktana, Inc., the leader in intelligent customer engagement for the global life sciences industry, today announced the Aktana Action Agent - designed to empower field teams and future-proof omnichannel engagement.
“The major players in Life Sciences CRM systems and Customer Data Platforms (CDPs) are changing roadmaps and partnerships, leaving pharma companies facing a serious innovation challenge.” said Derek Choy, Co-founder and Chief Product Officer of Aktana. “There’s an urgent need to help leaders find future-proofed solutions that address today’s business needs, as they confront expensive migration decisions in this shifting landscape.”
Aktana was recently named a Leader and one of only three Star Performers in the 2024 Life Sciences Next-Generation Customer Engagement Platform (CEP) PEAK Matrix® by Everest Group, cementing Aktana's position as a leading future-proof CEP.
“Life Sciences enterprises are increasingly prioritizing experience-driven Customer Engagement Platforms over traditional CRM systems, reflecting a significant shift towards customer-centric strategies,” said Chunky Satija, Vice President, Healthcare and Life Sciences, Everest Group.
Aktana Action Agent: Strategic Field Activity
Deeply integrated with Aktana’s Strategy Orchestration, Action Agent empowers life sciences teams to make smarter, data-driven decisions – harnessing the power of Large Language Models (LLMs). Purpose-built agents automate critical tasks such as:
1.) streamlining planning with suggested actions (forecasted to improve defined business outcomes);
2.) enabling pre-call preparation with insights tailored for each HCP;
3.) reducing logistical effort with automated call logging.
Faster Time-to-Value with CRM-Agnostic AI
Action Agent can be embedded into popular CRM systems like Veeva and Salesforce, giving customers optionality. Delivering immediate value on existing investments, Aktana ensures seamless migration so that customers are not locked into a siloed ecosystem.
Each agent is pre-configured so it can be deployed and scaled effortlessly, enabling customers to fill critical business gaps without migration delays. By providing a scalable and interoperable solution, Aktana Action Agent drives strategic alignment and delivers faster time-to-value for life sciences organizations.
Sign up for our webinar happening on Dec 12th to learn more about future-proof CRM strategies from our cofounder Derek Choy.
Learn more: Aktana Action Agent
About Aktana
Aktana provides AI-powered solutions tailored to the life sciences industry, enabling commercial teams to align strategies with customer needs, optimize engagement across channels, and deliver measurable impact.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241205089781/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
1NCE and Pessl Instruments Connect Smart Farms Worldwide29.7.2026 10:00:00 CEST | Press release
IoT specialists 1NCE and Pessl Instruments help farmers in 80 countries to connect and manage thousands of weather stations Smart farming solution improves water and fertilizer efficiency Both companies provide critical components at a 99.97% service availability 1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, and Pessl Instruments, a global leader in smart agriculture, announce today the roll-out of the METOS by Pessl Instruments weather network solution powered by 1NCE. The smart farming solution provided by Pessl Instruments connects thousands of weather stations and field sensors through a single platform, providing farmers real-time data of precipitation and soil moisture, extreme weather forecasting and crop disease risk in more than 80 countries. The main challenge for the deployment of smart farming solutions is always providing good coverage in rural areas. Thanks to 1NCE’s global connectivity service available in more
Cognita Reply Named an OpenAI Advanced Partner to Accelerate Enterprise Adoption of Frontier AI29.7.2026 10:00:00 CEST | Press release
Cognita Reply, the Reply Group company specialising in OpenAI technologies, today announced that it has been named an OpenAI Advanced Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729234340/en/ Cognita Reply, the Reply Group company specialising in OpenAI technologies, today announced that it has been named an OpenAI Advanced Partner within the OpenAI Partner Network, to accelerate enterprise adoption of frontier AI The OpenAI Partner Network is a global programme for partners to build, sell and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities and customer relationships, while equipping them with resources, enablement and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. We’re pleased to welcome Cognita Reply as an OpenAI Advanced Partner. The Cognita Reply
T964 Named as Uptime Institute Business Partner to Power Iraq’s Digital Infrastructure29.7.2026 09:02:00 CEST | Press release
Agreement signed at U.S.-Iraq Business Summit brings the world’s most trusted digital infrastructure standards to Iraq Uptime Institute and Tech964 Holding Limited (T964), Iraq’s leading digital infrastructure company, today announced a landmark strategic partnership to accelerate Iraq’s digital transformation. The partnership combines the world’s leading authority in digital infrastructure standards with the company building the critical infrastructure underpinning Iraq’s digital economy. The agreement was signed at the U.S. Chamber of Commerce U.S.-Iraq Business Summit on July 17, 2026, during the official U.S. visit of Iraqi Prime Minister Ali Al-Zaidi, at a historic summit that produced more than 50 agreements valued at over USD $60 billion and marked a powerful new era of economic cooperation between the United States and Iraq. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260728066813/en/ T964 named as Uptime Institut
ELFA Vape Aerosols Less Harmful Than Cigarette Smoke: Study29.7.2026 09:00:00 CEST | Press release
Levels of 17 analytes usually found in cigarette smoke tested in aerosols from ELFBAR ELFA pods 10 harmful constituents below detectable levels, with formaldehyde and acetaldehyde up to 99.9%* lower than those in cigarette smoke Metals detected well below safety thresholds Complete switching to ELFA significantly reduces or brings to zero adult users’ exposure to harmful constituents Levels of 17 constituents in aerosols from ELFA, a pod system vape by ELFBAR, are undetected or substantially lower than those in cigarette smoke, reveals the latest peer-reviewed study published by iScience, a scientific journal. Aerosols in this study are generated by facilities under standardized laboratory conditions. The tests involve 17 cigarette smoke-related analytes during vaporization of vape liquid from ELFA’s pods in four flavors, including Super Tobacco, Spearmint, Strawberry Ice and Watermelon. Findings indicate that adult smokers completely transitioning to ELFA pod system could reduce, or e
PK MED Strengthens Its Strategic and Scientific Governance to Support the Development of Its Therapeutic Micro-implants29.7.2026 09:00:00 CEST | Press release
François Romaneix is appointed Chairman of the Board of Directors.Prof. Philippe Leboulch joins the Board of Directors and the Scientific Advisory Board.Prof. Alain Fischer becomes Chairman of the Scientific Advisory Board.Isabelle Buckle and Tom Tice are appointed to the Board of Directors. PK MED, a French biotechnology company founded by Truffle Capital (founder of Abivax and Carvolix), developing therapeutic micro-implants to address major medical needs, today announces a significant strengthening of its governance. The company is strengthening the structure of its Board of Directors and Scientific Advisory Board to support the upcoming Phase 2 entry of its most advanced drug candidate, ARTHRELIS (treatment of gout flares), and to accelerate the preclinical development of ENGRAFTIS (treatment of poor graft function following bone marrow transplantation). The Board of Directors of PK MED welcomes four key new members: François Romaneix, appointed Chairman of the Board of Directors.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom